Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2019

View Archived Issues

Alpha-synuclein and autophagy

Hypothermia activates hypoxia protein, benefits metabolism

First green tea-triggered genetic control system reported

Positive clinical data presented for omburtamab

CLDN6 identified as a tumor-promoting gene in gastric cancer

Data presented for the oral, clinical stage, class I specific HDACi OKI-179

Kinesins are involved in the pathophysiology of genetically undiagnosed Rett syndrome

Adenoviral gene therapy rescues eukaryotic translation elongation factor 1 alpha 2 knockout in mice

New GABA-A receptor alpha 5 PAM with pro-cognitive, anxiolytic and antidepressant effects in mice

First patient dosed in phase I/II study of LNS-8801 in patients with advanced cancer

Themis Bioscience and CEPI initiate phase I study of Lassa fever vaccine candidate

FTO variant rs9939609 as a new genetic biomarker in Crohn's disease

FORMA Therapeutics discloses new histone deacetylase 8 inhibitors

Dihydroorotate dehydrogenase inhibitors discovered at Bayer

East China University of Science and Technology patents dihydroorotate dehydrogenase inhibitors

Dalian Institute of Chemical Physics CAS patents muscarinic M1/ M3 receptor antagonists

Proline derivatives identified at Qingdao Marine Biomedical Research Institute

Dosing begins in first-in-human study of UCARTCS1 for relapsed/refractory multiple myeloma

European Commission approves Dupixent for chronic rhinosinusitis with nasal polyposis

FDA places partial hold on AVXS-101 intrathecal clinical trials

CytomX initiates phase II study of CX-072 with ipilimumab in relapsed or refractory melanoma

miRagen Therapeutics reports on miR-29 programs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...